research Prostatakarzinom
5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
Search
for
Sort by
Research
780-810 / 1000+ results
research Assessment of the Pharmacokinetic -Pharmacodynamic Interaction Between Terazosin and Finasteride
Terazosin and finasteride together cause no major issues.
research The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
research Finasteride, a Type 2 5α-reductase inhibitor, in the treatment of men with androgenetic alopecia
Finasteride effectively treats male hair loss, improving growth and density.
research Alpha-blockers/finasteride: no benefit in ED
research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research Meta-Analysis of Randomized Clinical Trials of Finasteride
Finasteride effectively treats BPH and hair loss but may cause sexual side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF FINASTERIDE AND TAMSULOSIN IN TABLET FORMULATIONS
A reliable method was developed to measure Tamsulosin and Finasteride in tablets accurately.
research Clinical Study of Tolterodine Tartrate in the Treatment of Overactive Bladder
Tolterodine Tartrate effectively treats overactive bladder symptoms.
research 187 Protective Effect of DA-9401 on Acute use of Finasteride on Sprague–Dawley Rats
DA-9401 protects against hair loss, improves organ function, and prevents infertility caused by finasteride.
research Risk of Poor Glycemic Control in Tamsulosin Versus Finasteride Users with Type 2 Diabetes Mellitus
Tamsulosin and finasteride have similar effects on blood sugar control in men with type 2 diabetes.
research Screening and confirmation methods of the major urinary metabolite of finasteride–carboxy-finasteride by liquid chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry
New methods can detect finasteride's major urinary metabolite in urine for up to 49 hours.
research A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly l-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from
Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
research Finasteride and sexual side effects
Finasteride may cause sexual side effects like erectile dysfunction, but they are reversible and affect less than 2% of men.
research Finasteride
Finasteride treats hair loss and prostate issues by lowering certain hormone levels.
research Desferrioxamine treatment of aceruloplasminemia: Long‐term follow‐up
Finasteride may help reduce symptoms in male Tourette syndrome patients.
research Effectiveness of Topical Minoxidil (5%) Plus Topical Finasteride (0.1%) Fixed-Dose Combination Versus Topical Minoxidil (5%) Plus Oral Finasteride (1 Mg/Day) in Grade II-IV Androgenetic Alopecia: A Randomized, Double Blind Clinical Trial
research Long-Term Experience With 5-alpha-Reductase Inhibitors.
Finasteride reduces prostate size and symptoms with few side effects.
research Can we predict prostate size by scoring baldness? The relationship of androgenic alopecia and lower urinary tract symptoms
research Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure.
A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
research The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids
Low dose finasteride decreases certain steroids, possibly increasing depression risk.
research UV Spectrophotometric Stability Indicating Method Development and Validation for the Determination of Finasteride Bulk and Dosage Form.
The method accurately measures finasteride in bulk and dosage forms.
research 5α-Reductase inhibitor therapy: Should physicians be concerned with persistent diminished libido, erectile dysfunction and depression in a subset of patients?
Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
research Dual-phase release finasteride-loaded microspheres for androgenetic alopecia treatment: rapid intervention and sustained control of dihydrotestosterone
A new finasteride treatment may quickly and effectively promote hair regrowth.
research Comparison of Finasteride (Proscar®) and Serenoa repens (Permixon®) in the Inhibition of 5-Alpha Reductase in Healthy Male Volunteers
Finasteride works better than Permixon in reducing dihydrotestosterone levels.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research FINASTERIDE AS A TREATMENT FOR MALE ANDROGENETIC ALOPECIA
Finasteride effectively treats male pattern baldness.